Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 5 | 2022 | 566 | 1.370 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 658 | 0.860 |
Why?
|
| Genetic Vectors | 1 | 2022 | 107 | 0.800 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 31 | 0.750 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 72 | 0.740 |
Why?
|
| Transcription Factors | 2 | 2022 | 512 | 0.740 |
Why?
|
| Biological Products | 1 | 2022 | 60 | 0.740 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 114 | 0.720 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 245 | 0.710 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 185 | 0.670 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 50 | 0.490 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 340 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 143 | 0.460 |
Why?
|
| Protein Isoforms | 2 | 2022 | 118 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 445 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2022 | 251 | 0.360 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 447 | 0.340 |
Why?
|
| Metal Nanoparticles | 2 | 2022 | 128 | 0.330 |
Why?
|
| Animals | 8 | 2022 | 10078 | 0.330 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2009 | 29 | 0.320 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2008 | 13 | 0.300 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 177 | 0.300 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 31 | 0.300 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 32 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 103 | 0.290 |
Why?
|
| Female | 8 | 2022 | 14633 | 0.230 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 1405 | 0.220 |
Why?
|
| Cloning, Molecular | 2 | 2022 | 205 | 0.220 |
Why?
|
| Humans | 12 | 2022 | 27115 | 0.200 |
Why?
|
| Mammals | 1 | 2022 | 46 | 0.200 |
Why?
|
| Genomic Instability | 1 | 2021 | 33 | 0.190 |
Why?
|
| Mice | 4 | 2022 | 4472 | 0.190 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 201 | 0.190 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 109 | 0.180 |
Why?
|
| Mebendazole | 1 | 2020 | 10 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 151 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 127 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 149 | 0.170 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 750 | 0.160 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 1268 | 0.160 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 377 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2020 | 276 | 0.130 |
Why?
|
| Prognosis | 2 | 2009 | 763 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 12 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 17 | 0.130 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 42 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2015 | 108 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 133 | 0.120 |
Why?
|
| Oncolytic Virotherapy | 2 | 2011 | 12 | 0.120 |
Why?
|
| Vaccinia virus | 1 | 2011 | 6 | 0.100 |
Why?
|
| Apoptosis | 1 | 2015 | 740 | 0.100 |
Why?
|
| Mutation | 1 | 2015 | 818 | 0.090 |
Why?
|
| Alleles | 2 | 2009 | 345 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 57 | 0.090 |
Why?
|
| Genotype | 2 | 2009 | 443 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 229 | 0.090 |
Why?
|
| Gold | 2 | 2022 | 129 | 0.090 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 32 | 0.080 |
Why?
|
| Gene Expression | 2 | 2009 | 408 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2009 | 14 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2009 | 56 | 0.080 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2009 | 10 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2015 | 1379 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 92 | 0.080 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 11 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 90 | 0.080 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2008 | 11 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Hirudins | 1 | 2008 | 17 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2008 | 35 | 0.080 |
Why?
|
| Metalloendopeptidases | 1 | 2008 | 39 | 0.080 |
Why?
|
| Antithrombins | 1 | 2008 | 28 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2009 | 40 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 163 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2009 | 142 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 462 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 537 | 0.070 |
Why?
|
| Lung | 1 | 2009 | 363 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2008 | 331 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 655 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2008 | 635 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 1940 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2022 | 28 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 132 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 76 | 0.050 |
Why?
|
| Fenbendazole | 1 | 2020 | 8 | 0.050 |
Why?
|
| Quinuclidines | 1 | 2020 | 10 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2020 | 11 | 0.050 |
Why?
|
| Insulin | 1 | 2022 | 314 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 100 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 102 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 148 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 99 | 0.040 |
Why?
|
| Liposomes | 1 | 2020 | 142 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 195 | 0.040 |
Why?
|
| Aged | 1 | 2009 | 5221 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 262 | 0.040 |
Why?
|
| Middle Aged | 1 | 2009 | 6899 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 375 | 0.030 |
Why?
|
| Male | 1 | 2009 | 13019 | 0.030 |
Why?
|
| Virus Replication | 1 | 2011 | 63 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 150 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 313 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 285 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 455 | 0.020 |
Why?
|
| Gangliosides | 1 | 2009 | 3 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 2009 | 14 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 25 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2009 | 38 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2009 | 47 | 0.020 |
Why?
|
| Poland | 1 | 2009 | 5 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 189 | 0.020 |
Why?
|
| Nitroprusside | 1 | 2008 | 8 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2008 | 11 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 80 | 0.020 |
Why?
|
| Plasminogen | 1 | 2008 | 8 | 0.020 |
Why?
|
| Pichia | 1 | 2008 | 5 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 11 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 107 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2008 | 26 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 2008 | 21 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 144 | 0.020 |
Why?
|
| Oxidants | 1 | 2008 | 30 | 0.020 |
Why?
|
| Disulfides | 1 | 2008 | 33 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 143 | 0.020 |
Why?
|
| Epitopes | 1 | 2009 | 180 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2008 | 139 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 165 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2008 | 187 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 398 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2008 | 152 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 573 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 408 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 331 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 811 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 705 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 976 | 0.020 |
Why?
|